Sprycel (dasatinib) — Medica
Myeloid/lymphoid neoplasms with eosinophilia and ABL1 rearrangement
Initial criteria
- Patient is age ≥ 18 years.
- Tumor has an ABL1 rearrangement.
Reauthorization criteria
- Patient continues to meet initial criteria.
Approval duration
1 year